Part 1: Novo - Ambition vs. Reality
The CEO of Novo used Monday's Capital Markets Day to map out life after Wegovy and Ozempic's patents expire in the early 2030s: targeting more than five "multi-blockbuster" launches by 2030, over DKK150bn ($23bn) in risk-adjusted pipeline sales by 2035, and enough oral GLP-1 capacity to serve ten times more patients than today.
Sounds ambitious. But does the math math?
Novo currently serves ~1.5m people on the Wegovy pill. 10x that = 15 million - a tiny fraction of the 2 billion people living with obesity, overweight, or diabetes globally. This isn't a company chasing a small market; it's a company trying to capture a modest slice of an enormous one.
The growth target tells an even bigger corporate messaging story.
Revenue growth to 2030 is projected "in line with" pharma peers at ~5% annually. For a business that built its valuation on outgrowing the industry, "average" is a difficult reset for investors to swallow. From an IR standpoint, attempting to re-anchor market consensus around peer-group CAGR without formal guidance leaves investors filling in the blanks… which they usually fill with sell orders.
Monday didn't cause the sell-off; it confirmed the direction of travel.
Yet at ~10.7x trailing earnings and a ~4% divi yield, bulls argue the disappointment is fully priced in. The strategic question for institutional holders now becomes simple: Is Novo a growth engine losing steam, or a high-margin cash generator undergoing a classic multiple compression?
"Investors hoped for a project 'miracle'... For obvious reasons that miracle does not exist." — Per Hansen, Savings Economist at Nordnet |
The real tragedy of Monday's communications execution was the buried lead: new CagriSema data showed it beating Eli Lilly's tirzepatide head-to-head in the REIMAGINE 5 trial (12.4% vs 9.1% weight loss at week 60 in adults with type 2 diabetes). It's a genuine clinical win that should have anchored the bull case, but was completely overshadowed by top-line growth fatigue.
Add in strong cash generation funding its $23 billion pipeline target & the underlying fundamentals remain formidable. But until management can prove CagriSema's commercial moat before the patent cliff hits, I imagine this will remain a “show-me” story for investors.
Part 2: Crypto - Squeezes, Flows & Breakeven
Yikes. A number go up day in the world of crypto. MSTR alone added ca.$5.4 billion in market cap. The HODLers are proclaiming that the bottom is in!
More than $600m of crypto positions were liquidated over 24 hours. In the key hour, roughly $313m was wiped out - 96% of it from shorts. That's forced buying doing exactly what forced buying does: turning a move into a move.
There's a genuinely interesting data point underneath the noise.
Glassnode puts the average cost for US spot Bitcoin ETF investors at around $85,638. Bitcoin has now effectively reached it.
This entire cohort has spent months sitting underwater. The market is now asking whether breakeven becomes a ceiling or a launchpad.
The flows are interesting too.
Fidelity's FBTC took in $310.7m on Friday, versus $324.6m across the US spot Bitcoin ETF complex. BlackRock's IBIT, which usually dominates the flows, recorded no net inflow that day.
Technically, BTC has also reclaimed its 50-week moving average - another reason trend-followers are paying attention.
So: still not proof of decoupling.
What it does show is how positioning has become vulnerable on both sides - short enough to rip on a squeeze, long enough that ETF holders are staring at breakeven.
That doesn’t feel like a market with conviction, but one waiting to be told which way to go.
Part 3: Market Go Up
Yesterday wasn’t just about crypto… The MAG 7 added roughly $500bn of market cap.
AMD crossed a $1 trillion valuation / Meta is up 25% this month / Intel up 35%.
Fundstrat's Tom Lee called it exactly what it is on CNBC this morning: a "face ripper" in stocks and in crypto both. His mechanism is the same one running through this whole issue: last week was maximum pain (a hawkish Fed, high oil, high rates); over the weekend oil cooled, and the market's now betting a maximum-hawkish Fed has nowhere to go but ease off. Oil down, yields down, risk assets up. Lee's contrarian case: sentiment was at rock-bottom bearishness last week & a market full of people caught offside can run further than it should.
Not everyone's convinced it's the real thing: technician Jay Woods points out nothing has fundamentally changed in a single day and flags Micron's earnings next week as the actual test. Worth remembering too: diesel is still sitting above $6.80 a gallon, a genuine cost pressure quietly sitting underneath all the risk-on cheer.
Bottom line: GLA & DYOR.
Important Disclaimer
This publication is published by James Lea / CorpCast. The information provided herein is for educational, informational, and market commentary purposes only and does not constitute financial, investment, tax, or legal advice. Opinions expressed reflect analytical views at the time of publication (22 September 2026) and are subject to change without notice. Disclosures: The author may hold positions in securities or digital assets discussed. Always conduct independent research and consult an authorized financial advisor before making capital allocation decisions (GLA & DYOR).